These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9661013)

  • 1. Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model.
    Corvaisier S; Maire PH; Bouvier d'Yvoire MY; Barbaut X; Bleyzac N; Jelliffe RW
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1731-7. PubMed ID: 9661013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.
    den Hollander JG; Mouton JW; Verbrugh HA
    Antimicrob Agents Chemother; 1998 Apr; 42(4):744-8. PubMed ID: 9559776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of tobramycin in patients with cystic fibrosis.
    Mouton JW; Jacobs N; Tiddens H; Horrevorts AM
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
    Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.
    Mouton JW; van Ogtrop ML; Andes D; Craig WA
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2473-8. PubMed ID: 10508027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics.
    Kitamura Y; Yoshida K; Kusama M; Sugiyama Y
    Drug Metab Pharmacokinet; 2014; 29(6):455-62. PubMed ID: 25008846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
    MacGowan A; Rogers C; Holt HA; Wootton M; Bowker K
    J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of pharmacokinetic/pharmacodynamic relationships of PD-0162819, a biotin carboxylase inhibitor representing a new class of antibacterial compounds, using in vitro infection models.
    Ogden A; Kuhn M; Dority M; Buist S; Mehrens S; Zhu T; Xiao D; Miller JR; Hanna D
    Antimicrob Agents Chemother; 2012 Jan; 56(1):124-9. PubMed ID: 21986824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.
    Schentag JJ; Nix DE; Adelman MH
    DICP; 1991 Oct; 25(10):1050-7. PubMed ID: 1803788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
    Schentag JJ
    J Chemother; 1999 Dec; 11(6):426-39. PubMed ID: 10678784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model.
    Zhu ZY; Li RC
    J Antimicrob Chemother; 1998 Jul; 42(1):61-5. PubMed ID: 9700529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
    Katsube T; Yamano Y; Yano Y
    J Pharm Sci; 2008 Apr; 97(4):1606-14. PubMed ID: 17705288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The integration of four major determinants of antibiotic action: bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics.
    Li RC; Zhu ZY
    J Chemother; 2002 Dec; 14(6):579-83. PubMed ID: 12583549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model.
    Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH; Firsov AA
    Int J Antimicrob Agents; 2007 Feb; 29(2):165-9. PubMed ID: 17207607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
    Zhanel GG; Johanson C; Laing N; Hisanaga T; Wierzbowski A; Hoban DJ
    Antimicrob Agents Chemother; 2005 May; 49(5):1943-8. PubMed ID: 15855517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What do we really know about antibiotic pharmacodynamics?
    Gunderson BW; Ross GH; Ibrahim KH; Rotschafer JC
    Pharmacotherapy; 2001 Nov; 21(11 Pt 2):302S-318S. PubMed ID: 11714222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.